The "Advanced Therapy Medicinal Products - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

The global market for Advanced Therapy Medicinal Products was valued at US$13 Billion in 2024 and is projected to reach US$25.4 Billion by 2030, growing at a CAGR of 11.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Advanced Therapy Medicinal Products Market - Key Trends & Drivers Summarized

Advanced Therapy Medicinal Products (ATMPs) represent a frontier in medical innovation, encompassing gene therapies, cell therapies, and tissue-engineered products designed to treat, diagnose, or prevent diseases through advanced biological methods. ATMPs offer groundbreaking treatments for conditions that are currently difficult or impossible to treat with conventional medicines, including various cancers, genetic disorders, and degenerative diseases. These therapies work by modifying the genetic makeup of cells, harnessing the body's own repair mechanisms, or replacing damaged tissues, thus providing highly personalized and potentially curative treatments. The development and approval of ATMPs are subject to stringent regulatory processes, ensuring their safety, efficacy, and quality.

The field of ATMPs has seen rapid advancements due to significant progress in biotechnology and a deeper understanding of genetic and cellular mechanisms. Innovations such as CRISPR-Cas9 gene editing, induced pluripotent stem cells (iPSCs), and advanced tissue scaffolding techniques have expanded the possibilities for developing effective and targeted therapies. The growing number of clinical trials and successful approvals of ATMPs by regulatory bodies such as the FDA and EMA highlight their therapeutic potential and market viability. Collaborations between academic institutions, biotech companies, and pharmaceutical giants are accelerating the development pipeline, bringing more ATMPs closer to commercialization. Additionally, advancements in manufacturing technologies and scalable production processes are making these therapies more accessible and cost-effective.

The growth in the ATMP market is driven by several factors. Firstly, the increasing prevalence of chronic and genetic diseases, which are often inadequately addressed by traditional treatments, is driving demand for innovative therapies like ATMPs. Secondly, significant advancements in biotechnology and genetic engineering are enabling the development of more effective and personalized ATMPs. Thirdly, substantial investments in research and development by biotech firms and pharmaceutical companies are accelerating the discovery and commercialization of new ATMPs.

Additionally, the favorable regulatory environment and expedited approval pathways for breakthrough therapies are facilitating faster market entry for ATMPs. Lastly, the growing patient and physician awareness of the benefits of advanced therapies, coupled with the expanding infrastructure for ATMP manufacturing and distribution, are further propelling the market's growth.

Scope of the Study

The report analyzes the Advanced Therapy Medicinal Products market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments:

• Type (Tissue Engineered Products, Cell Therapy, Gene Therapy, CAR-T Therapy)

Geographic Regions/Countries:

• World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Tissue Engineered Products segment, which is expected to reach US$10.5 Billion by 2030 with a CAGR of a 12.5%. The Cell Therapy segment is also set to grow at 11.1% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $5.6 Billion in 2024, and China, forecasted to grow at an impressive 10.2% CAGR to reach $1.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players such as Bluebird Bio Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., JCR Pharmaceuticals Co. Ltd. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Key Questions Answered:

• How is the Global Advanced Therapy Medicinal Products Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Key Attributes:

Key Topics Covered:

MARKET OVERVIEW

• A Prelude to Advanced Therapy Medicinal Products (ATMP)
• ATMPs' Costs and Availability
• Global Economic Outlook
• Global Market Prospects and Outlook
• Advanced Therapy Medicinal Products Market Poised to Witness Rapid Growth
• Growth Drivers and Challenges
• ATMP Marketing Authorisations: An Insight
• North America and Europe Dominate, Asia-Pacific to Exhibit Fastest Growth
• Competition
• Recent Market Activity
• Advanced Therapy Medicinal Products - Global Key Competitors Percentage Market Share in 2024
• Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024

MARKET TRENDS & DRIVERS

• Rising Geriatric Population and Subsequent Growth in Prevalence of Neurological Disorders Drive Market Demand
• Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
• Regenerative Medicine: A Promising Area for Advanced Therapy Medicinal Products
• Global Regenerative Medicine Market Size in US$ Billion for 2019, 2021, 2023 and 2025
• Global Regenerative Medicines Market by Category: Breakdown (in %) for Biomaterials, Stem Cell Therapies and Tissue Engineering for 2022
• Stem Cell Therapy: A Promising Avenue for Nerve Repair and Regeneration
• Rising Demand for Gene Therapy Spurs Market Expansion
• List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
• Top Ten Genetic Diseases Worldwide
• Oncology Represents the Largest Indication for Gene Therapy
• Uptrend in Healthcare Spending Creates Fertile Environment
• World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
• Expanding Role of Advanced Therapy Medicinal Products Market in Personalized Medicine
• Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
• World Personalized Medicine Market by Region/Country (2022): Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World
• Biotech Research Spending Patterns Steer Momentum

FOCUS ON SELECT PLAYERS

• Bluebird Bio Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• JCR Pharmaceuticals Co. Ltd.
• Kolon TissueGene, Inc.
• MEDIPOST Co., Ltd.
• Novartis AG
• Organogenesis Inc.
• Spark Therapeutics, Inc.
• UniQure N.V.
• Vericel Corporation

For more information about this report visit https://www.researchandmarkets.com/r/7gqtdq

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250421742185/en/